Markers of beta-cell dysfunction associated with high rate of progression to type 1 diabetes

June 18, 2013

The majority of children at risk of type 1 diabetes who developed 2 or more diabetes-related autoantibodies developed type 1 diabetes within 15 years, findings that highlight the need for research into finding interventions to stop the development of multiple islet autoantibodies, according to a study in the June 19 issue of JAMA.

" is a that often manifests during childhood and adolescence. The lifelong requirement for and the many complications that follow the diagnosis can be difficult for those affected. Type 1 diabetes usually has a preclinical phase that can be identified by the presence of autoantibodies to antigens of the ," according to background information in the article. The rate of progression to diabetes after seroconversion to islet autoantibodies is uncertain.

Anette G. Ziegler, M.D., of Helmholtz Zentrum Munchen, Neuherberg, Germany, and colleagues conducted a study to estimate rates of progression to type 1 diabetes and associated characteristics based on islet autoantibody status. For the study, data were pooled from prospective cohort studies performed in Colorado (recruitment, 1993-2006), Finland (recruitment, 1994-2009), and Germany (recruitment, 1989-2006) examining children genetically at risk for type 1 diabetes for the development of insulin autoantibodies, decarboxylase 65 (GAD65) autoantibodies, insulinoma antigen 2 (IA2) autoantibodies, and diabetes. Participants were all children recruited and followed up in the 3 studies (Colorado, 1,962; Finland, 8,597; Germany, 2,818). Follow-up assessment in each study was concluded by July 2012.

The researchers found that progression to type 1 diabetes at 10-year follow-up after islet autoantibody seroconversion in 585 children with multiple islet autoantibodies was 69.7 percent, and in 474 children with a single islet autoantibody was 14.5 percent. Risk of diabetes in children who had no islet autoantibodies was 0.4 percent by the age of 15 years.

A total of 355 children (60.7 percent) with multiple islet autoantibodies progressed to diabetes at a median (midpoint) follow-up time after seroconversion of 3.5 years, and a median age of 6.1 years. Progression to diabetes after seroconversion was 43.5 percent at 5-year follow-up, 69.7 percent at the 10-year follow-up, and 84.2 percent at the 15-year follow-up.

Analysis indicated that more rapid progression to diabetes after seroconversion was associated with younger age at seroconversion (younger than age 3 years [10-year risk, 74.9 percent] vs. children 3 years or older [60.9 percent]); and female sex (10-year risk of 74.8 percent for girls vs. 65.7 percent for boys).

"These data show that the detection of multiple islet autoantibodies in children who are genetically at risk marks a preclinical stage of type 1 diabetes. … Thus, the development of multiple islet autoantibodies in predicts type 1 diabetes," the authors write. "Future prevention studies should focus on this high-risk population."

Jay S. Skyler, M.D., and Jay M. Sosenko, M.D., of the University of Miami Miller School of Medicine, write in an accompanying editorial that the nearly inevitable progression of individuals from seropositivity to type 1 diabetes (T1D) in the current report by Ziegler et al "serves to raise the question of whether the definition of T1D needs updating, perhaps broadening to include a prediabetic state."

"Current criteria for overt diabetes are based on what is used for type 2 diabetes. Yet the sequence of events in diabetes development suggests it is possible to modify the definition at least to include individuals who are seropositive with either dysglycemia or a high T1D risk score. This would allow potential intervention with immunomodulatory therapies directed at preservation of beta-cell function measured by C-peptide. Data from the Control and Complications Trial have demonstrated that preservation of C-peptide results in reduced risk of severe hypoglycemia and of progression of retinopathy and nephropathy."

Explore further: Increasing shift from islet antibody positivity to diabetes

More information: JAMA. 2013;309(23):2473-2479
JAMA. 2013;309(23):2491-2492

Related Stories

Increasing shift from islet antibody positivity to diabetes

March 2, 2012

(HealthDay) -- There is an increase in both the prevalence and levels of islet antigen-2 and zinc transporter 8, as well as in autoantibodies, in newly diagnosed type 1 diabetes patients during a period of rising disease ...

Stopping diabetes with insulin tablets

September 19, 2012

Type 1 diabetes is the autoimmune form of diabetes, in which the patients' insulin-producing beta cells are destroyed by their own immune system.

Islet transplant may slow progression of atherosclerosis

January 28, 2013

Minimally invasive islet transplantation for patients with type 1 diabetes achieves insulin independence and reverses the progression of atherosclerosis in the first few years after transplant, according to a University of ...

Recommended for you

Drug prevents type 1 diabetes in mice, study finds

September 14, 2015

The buildup of a substance in the pancreas during the pre-symptomatic stage of Type 1 diabetes is essential to the development of the disease, Stanford University School of Medicine researchers have shown.

Bacteria may cause type 2 diabetes

June 1, 2015

Bacteria and viruses have an obvious role in causing infectious diseases, but microbes have also been identified as the surprising cause of other illnesses, including cervical cancer (Human papilloma virus) and stomach ulcers ...

Engineered hot fat implants reduce weight gain in mice

August 20, 2015

Scientists at the University of California, Berkeley, have developed a novel way to engineer the growth and expansion of energy-burning "good" fat, and then found that this fat helped reduce weight gain and lower blood glucose ...


Please sign in to add a comment. Registration is free, and takes less than a minute. Read more

Click here to reset your password.
Sign in to get notified via email when new comments are made.